Cardiff Oncology Capex To Depreciation Over Time
| CRDF Stock | USD 3.78 1.34 54.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cardiff Oncology Performance and Cardiff Oncology Correlation. Cardiff |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.015 | Quarterly Revenue Growth 0.17 | Return On Assets (0.38) | Return On Equity (0.68) |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capex To Depreciation Analysis
Compare Cardiff Oncology and related stocks such as Reviva Pharmaceuticals, Effector Therapeutics, and PDS Biotechnology Corp Capex To Depreciation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PDSB | 30.8042 | 30.8042 | 30.8042 | 30.8042 | 28.3324 | 24.5705 | 6.859 | 1.0317 | 2.0E-4 | 2.0E-4 | 2.0E-4 | 2.0E-4 | 2.0E-4 | 3.0E-4 | 3.0E-4 |
| RVPHW | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EYEN | 0.5122 | 0.5122 | 0.5122 | 0.5122 | 0.5122 | 0.5122 | 3.3681 | 0.4019 | 1.4589 | 10.8612 | 2.7381 | 7.305 | 2.8453 | 5.0696 | 3.07 |
| CGTX | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 1.7778 | 0.102 | 0.2903 | 0.7277 | 0.5833 | 0.77 |
| RNAZ | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 1.0235 | 0.0689 | 0.0655 |
| KOD | 0.3807 | 0.3807 | 0.3807 | 0.3807 | 0.3807 | 0.3807 | 0.3807 | 0.3807 | 1.1857 | 0.4797 | 1.663 | 7.2664 | 4.3053 | 1.5966 | 1.93 |
| SLS | 6.3611 | 0.3252 | 35.0619 | 35.0619 | 6.2182 | 0.431 | 0.0423 | 9.8468 | 9.8468 | 9.8468 | 9.8468 | 9.8468 | 9.8468 | 8.86 | 4.86 |
| NLSP | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 3.9363 | 4.0E-4 | 4.0E-4 | 4.0E-4 |
| MREO | 0.1053 | 0.1053 | 0.1053 | 0.1053 | 0.1053 | 0.1053 | 0.1053 | 63.6314 | 0.9402 | 0.0133 | 0.01 | 0.8333 | 0.0138 | 0.3949 | 0.38 |
| DAWN | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 0.5935 | 40.201 | 0.049 | 8.4178 | 13.55 |
| INAB | 7.8854 | 7.8854 | 7.8854 | 7.8854 | 7.8854 | 7.8854 | 7.8854 | 7.8854 | 7.8854 | 3.4375 | 0.3921 | 0.3921 | 3.359 | 0.2399 | 0.23 |
| CUE | 16.8311 | 16.8311 | 16.8311 | 16.8311 | 16.8311 | 16.8311 | 2.5533 | 2.8719 | 2.4398 | 0.009 | 0.5629 | (0.5135) | 0.0945 | 0.11 | 0.1 |
| LTRN | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 3.5138 | 4.763 | 2.2924 | 2.762 | 1.2818 | 1.22 |
| CGEM | 6.0698 | 6.0698 | 6.0698 | 6.0698 | 6.0698 | 6.0698 | 6.0698 | 6.0698 | 6.0698 | 0.2857 | 0.1613 | 11.1175 | 12.1828 | 0.671 | 0.64 |
| BOLT | 0.9603 | 0.9603 | 0.9603 | 0.9603 | 0.9603 | 0.9603 | 0.9603 | 0.9603 | 0.9603 | 1.5164 | 5.3388 | 1.9598 | 1.1723 | 0.1111 | 0.11 |
| LYRA | 0.4512 | 0.4512 | 0.4512 | 0.4512 | 0.4512 | 0.4512 | 0.4512 | 0.4512 | 0.4512 | 7.8148 | 18.6842 | 3.3816 | 0.1537 | 3.7662 | 6.28 |
Cardiff Oncology and related stocks such as Reviva Pharmaceuticals, Effector Therapeutics, and PDS Biotechnology Corp Capex To Depreciation description
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.My Equities
My Current Equities and Potential Positions
| Cardiff Oncology | CRDF |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.78
Check out Cardiff Oncology Performance and Cardiff Oncology Correlation. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Cardiff Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.